In 2013, Mirna Therapeutics announced that its new outside board member will be Clay Siegall Ph.D. Siegall currently serves as the CEO, President, and board Chairman of Seattle Genetics. Mirna Therapeutics is a privately-held company that was established in 2007 and is located in Austin, Texas. It concentrates on the development of microRNA in therapeutics.
Currently, the company has focused its attention on cancer research, an area that Clay Siegall has a ton of experience in. The CEO and President of Mirna Therapeutics, Dr. Paul Lammers, reiterated that the company was thrilled to welcome Siegall and looked forward to picking his brain on several areas relevant to their research especially their microRNA therapeutics.
Seattle Genetics is a prominent biotechnology company that primarily develops clinical products. Founded in 1998, the company has come a long way from its inception to the development of its latest cutting edge innovation, the antibody-drug conjugate (ADC). The company’s headquarters are found in Bothell Washington. The company has partnered with several leading organizations including Curagen, Medimmune, Genentech and Bayer Pharmaceuticals.
Clay Siegall Ph.D.
Clay Siegall is one of the co-founders of Seattle Genetics. Today, he is the CEO of the company. He also chairs the board of directors. The highly accomplished scientist has dedicated his life in the development of targeted cancer therapies that are needed in the research, treatment, and cure of cancer. He has maintained a foundation of rigorous research, drug development practices, and scientific innovation within Seattle Genetics.
Clay Siegall has guided Seattle Genetics’ capital raising activities. To date, the company has secured over $675 million in private and public financing thanks to the networking efforts of Clay Siegall. He led the initial public offering (IPO) of the company in 2001. Siegall has a Genetics Ph.D. from George Washington University. He also holds a Bachelor of Science in Zoology studies from the acclaimed University of Maryland.
Siegall has been instrumental in the development and deployment of antibody-drug conjugates (ADCs) currently used in the treatment of cancer. To date, he is a published author whose is accredited with over 70 publications. He also holds an incredible 15 patents to his name.